Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

CHENG-HONG TSAIFENG-MING TIENHSIN-AN HOUJia-Hau LiuSHANG-JU WUYu-Wen WangCHIEN-CHIN LINBOR-SHENG KOWEN-CHIEN CHOUYUN-CHU LINChieh-Lung ChengLI-CHUN LUSUNG-HSIN KUOMING YAORUEY-LONG HONGTAI-CHUNG HUANG2025-03-172025-03-172020-11-05https://scholars.lib.ntu.edu.tw/handle/123456789/725702Disclosures Tsai: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Chugai: Honoraria; Harvester: Honoraria; Janssen: Honoraria; Kirin: Honoraria; Takeda: Honoraria; BMS: Honoraria; Astellas: Honoraria; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Research Funding; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Ko:Roche: Honoraria. Cheng:Roche: Honoraria. Huang:MundiPharma: Honoraria; Chugai: Honoraria; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Janssen: Honoraria; Takeda: Honoraria; Bristol Meyer & Squibb: Honoraria.[SDGs]SDG3Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphomajournal article10.1182/blood-2020-138481